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Abstract: Simpler and more rapid approaches for therapeutic drug-level monitoring are highly 
desirable to enable use at the point-of-care. We have developed an all-electronic approach for 
detection of the HIV drug tenofovir based on scalable fabrication of arrays of graphene field-effect 
transistors (GFETs) functionalized with a commercially available DNA aptamer. The shift in the 
Dirac voltage of the GFETs varied systematically with the concentration of tenofovir in deionized 
water, with a detection limit less than 1 ng/mL. Tests against a set of negative controls confirmed 
the specificity of the sensor response. This approach offers the potential for further development 
into a rapid and convenient point-of-care tool with clinically relevant performance. 
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Therapeutic drug monitoring (TDM) is crucial for treating patients safely and appropriately as well 
as for developing new medications. It is particularly important to oversee the consumption of drugs 
with narrow therapeutic ranges and marked pharmacokinetic variability in target concentrations 
that are difficult to monitor, and drugs known to cause adverse effects1 both in individuals and 
communities.  Conventional TDM, however, is based on analytical techniques, such as liquid 
chromatography and mass spectrometry (LC-MS) that are expensive, time-consuming, and not 
suitable for clinical use2. In this study, we describe the fabrication of nanosensors potentially 
useful for monitoring the HIV medication tenofovir, with a methodology that leverages the 
remarkable sensitivity of the two-dimensional material graphene3, a highly reproducible and 
robust fabrication method for graphene field effect transistors (GFETs), and an effective, 
commercially-obtained aptamer with high affinity for tenofovir, a relevant drug metabolite. 
 
Aptamers are oligonucleotide biorecognition elements selected to bind to a particular target4, for 
which there are relatively few reports of use with scalable GFETs5,6,7,8. It is also possible to 
integrate aptamer biorecognition layers with metal-oxide-silicon field effect transistors (MOSFETs) 
using an extended gate geometry9. The aptamer used here was obtained commercially (Base 
Pair Technologies) and has been selected to bind to a metabolite of the HIV market prodrug 
tenofovir alafenamide. Tenofovir detection is of particular interest as the medication is often used 
to treat patients affected with HIV by reducing the virus count in the blood of the patient, and 
therefore decreasing the chance of the development of AIDS. Additionally, hepatitis B virus (HBV) 
is an accompanying ailment in HIV patients, and tenofovir treatments have shown to reduce the 
likelihood of HBV forming drug-resistant mutations, making it more suitable for the treatment of 
HIV than competing drugs10. In 2015, Koehn et al reached tenofovir detection limits of 0.5 ng/mL 
in plasma and cell samples using a method based on liquid chromatography-mass spectrometry 
(LC-MS)11. Such testing is potentially useful for monitoring therapy and to prevent drug 
accumulation and toxicity in patients with kidney or liver problems. However, despite the fact that 
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this detection limit is much more sensitive than required for TDM of tenofovir, the cost and slow 
speed of LC-MS make the approach inconvenient for a clinical setting. All-electronic nano-
enabled sensors offer a promising pathway towards a low-cost, rapid testing method suitable for 
use in the clinic or home. 
 
Here we report development of scalable graphene aptasensors for tenofovir based on back-gated 
GFETs functionalized with a tenofovir aptamer with a limit of detection of approximately 300 
pg/mL (~1 nM). We prepared graphene by chemical vapor deposition and fabricated GFETs using 
a robust and reproducible photolithographic process, with the GFETs showing a high yield (> 90%) 
and consistent electronic properties12. The chemical functionalization procedure provided high 
surface coverage with the aptamer, as determined using atomic force microscopy (AFM). The 
aptasensors showed a wide useful range (about a factor of 1000 in concentration) and high 
selectivity against related drug compounds. Our approach offers the potential for further 
development into a rapid and convenient point-of-care tool with clinically relevant performance. 
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Figure 1. (a) Raman spectrum of chemical-vapor-deposition-grown graphene on copper foil. (b) 
Three optical images of the sensor array. The left panel is a photograph of an array of 52 graphene 
field effect transistors (GFETs). The right panel has two optical micrographs at different 
magnifications. The top micrograph shows a region with vertical source electrodes and horizontal 
drain electrodes. The lower micrograph is zoomed in to show a single GFET, with a box outlining 
the graphene channel. (d) Current-gate voltage characteristic of graphene field effect transistors, 
showing good device uniformity. (e) Atomic Force Microscope (AFM) line scan for annealed 
graphene on SiO2. The height of the graphene is ~1 nm, as expected for monolayer graphene 
after transfer onto SiO2. Inset: AFM topographic image with the scan line indicated in blue. (f) 
AFM line scan of annealed graphene on SiO2 after functionalization with 1-Pyrenebutyric acid N-
hydroxysuccinimide ester linker and the tenofovir aptamer. The step height is ~3 nm, consistent 
with the expected heights for the molecular structure. Inset: AFM topographic image with the scan 
line shown in blue. 
 
Experiments were based on arrays of 52 devices, with graphene grown by chemical vapor 
deposition (CVD) on a catalytic copper foil using methane as the carbon feedstock. The 
monolayer graphene film was transferred onto a pre-patterned array of Cr/Au contacts on an 
Si/SiO2 wafer (chip size of 2.5 cm x 2 cm) through an electrolysis bubbling method13. The quality 
of the graphene was confirmed via Raman spectroscopy (Fig. 1a), showing 2D/G ratio of about 
2, as expected for monolayer graphene14. GFET channels (10 μm x 100 μm) were defined using 
photolithography and plasma etching, and the completed GFET arrays (Fig. 1 b,c) were cleaned 
by annealing in forming gas to minimize contaminants. Additional details of the fabrication are 
provided in the Methods section. 
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Current-backgate voltage (I-Vg) measurements showed good device-to-device uniformity across 
the array (Fig. 1d), and the I-Vg characteristics were analyzed by fitting the data to the form15:  
     𝐼−1 = [𝑒𝛼µ(𝑉𝑏𝑔 − 𝑉𝐷)]
−1
+ 𝐼𝑆
−1   (1) 
where I is the measured current, µ the carrier mobility, 𝑉𝑏𝑔 the back-gate voltage, 𝑉𝐷 the Dirac 
voltage, α the constant relating gate voltage to carrier number density, and 𝐼𝑆  the saturation 
constant due to short-range scattering16. The best fit values for the Dirac voltage and carrier 
mobility were typically in the range 0-5 V (2.35 ± 1.76 V) with an average mobility of 2,654 ± 115 
cm2/V-s. 
 
As-fabricated GFETs were functionalized with a commercial tenofovir aptamer using a well-
controlled chemical treatment. First, the GFET array was incubated for ~ 20 hours in a solution of 
the linker molecule 1-Pyrenebutyric acid N-hydroxysuccinimide ester (P-BASE) at a concentration 
of 1µM in dimethylformamide (DMF). P-BASE is known to bind with high affinity to graphene via 
π-π stacking17. Following the instructions of the manufacturer, the aminated tenofovir aptamer 
solution (1 μM in phosphate-buffer of pH = 7.6) underwent a heat treatment in order to obtain the 
desired conformation of the aptamer, and the devices were incubated in this solution for 3 hours 
following pyrene attachment. Results of the functionalization process were visualized by AFM (Fig. 
1 e, f). The height of bare graphene on silicon oxide was ~ 1 nm, while after binding of the linker 
and aptamer, the height of the structure had increased to ~ 3 nm, consistent with expectations 
given the molecular structures as well as our earlier report for functionalization of graphene with 
single-stranded DNA using the same linker molecule12. 
 
For testing of sensor responses, all 52 aptasensors in a single array were tested against a solution 
with a known concentration of tenofovir or a related control compound in deionized (DI) water. 
The solution was pipetted onto the array and left for one hour in order to allow the tenofovir target 
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to bind to the aptamer layer. After incubation, we observed a consistent shift of the Dirac point to 
more positive gate voltage (Fig. 2a), ∆𝑉𝐷. The sensor array response was taken to be the average  
Dirac voltage shift relative to ∆𝑉𝐷
0, the shift measured upon exposure to deionized water:  ∆𝑉𝐷
𝑅𝐸𝐿 =
∆𝑉𝐷 − ∆𝑉𝐷
0. This relative shift varied systematically with tenofovir concentration (Fig. 2b) and is 
attributed to an increase in the hole concentration in the GFET due to chemical gating18 induced 
by tenofovir binding. Tenofovir contains an amine group and a phosphate group, so it is expected 
to take on a charge of –e at pH 7.  
 
The Hill-Langmuir model for ligand binding in equilibrium provides an excellent fit to the data for 
∆𝑉𝐷
𝑅𝐸𝐿 as a function of tenofovir concentration  
∆𝑉𝐷
𝑅𝐸𝐿 = 𝐴
(𝑐 𝐾𝑎⁄ )
𝑛
1+(𝑐 𝐾𝑎⁄ )𝑛
+ 𝑍     (2) 
In this equation, A represents the maximum response with all binding sites occupied, c is the 
tenofovir concentration, Ka is the tenofovir concentration producing half occupation of a binding 
site, and n is the Hill coefficient. For the data in Fig. 2b, the best-fit parameters are A= 9.2 ± 0.2 
V, Ka = 3.8 ± 1.5 ng/mL, and n = 1.1 ± 0.3, which is consistent with independent binding of the 
target19. Assuming a charge of –e for tenofovir, the shift of ~9 V corresponds to a tenofovir density 
of 1.1x103 μm-2 when binding is saturated. The GFET tenofovir aptasensors described here have 
a limit of detection below 1 ng/mL, comparable to that reported for LC-MS, but implemented in a 
simpler, manufacturable, all-electronic format. 
 
To verify that the sensor response reflected specific binding of tenofovir to the aptamer, tests 
were conducted against three different HIV drugs as negative controls (lamivudine, abacavir, and 
emtricitabine), each at a concentration of 200 ng/mL, which for tenofovir would saturate the sensor 
response. As shown in Fig. 2b, the sensor response to emtricitabine was zero within statistical 
error, while abacavir and lamivudine gave small but statistically significant responses. This is 
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ascribed to a degree of structural similarity between these compounds and tenofovir that allows 
for some small binding probability to the aptamer. In a separate control experiment, an array of 
unfunctionalized graphene FETs was tested against tenofovir at a concentration of 3 𝜇g/mL, a 
concentration that would saturate the response of the graphene aptasensor. As shown in Fig. 2b, 
the response of the FET array was zero, within statistical error. Overall the results of these control 
experiments provide strong evidence that the aptasensor response to tenofovir reflects specific 
binding to the immobilized aptamer. 
 
Figure 2. (a) I-Vg curves for an as-fabricated graphene field effect transistor (GFET; black data), 
the GFET after functionalization with the aptamer (blue data) and after exposure to tenofovir at 3 
µg/mL. (b) Relative Dirac voltage shift as a function of tenofovir concentration. The error bars are 
calculated as the standard error of the mean. The red curve is a fit to the data based upon the 
Langmuir-Hill model as described in the text. The limit of detection is < 1 ng/mL. Data points 
associated with negative control experiments are also shown; when no error bar is plotted, the 
error bar is smaller than the size of the plotted symbol. The near null response for the negative 
controls provides very strong evidence that the dose-response curve reflects specific binding of 
the tenofovir target and the aptamer. 
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Conclusions 
We have successfully created a scalable approach for fabrication of arrays of GFET-based 
aptasensors and demonstrated sensitive (~1 nM) and specific detection of the target tenofovir, 
with a process based on CVD-grown graphene and photolithographic processing, making it 
suitable for scale-up to industrial production20.  Our GFET aptasensors have a wide analytical 
range and sensitivity comparable to LC-MS. Further work is required to optimize the aptasensor 
performance when applied to real human samples, but their simpler electronic format could make 
them more suitable for use in a point-of-care setting. For this work, the aptamer was obtained 
commercially, but we have recently extended the approach to a novel aptamer against azole class 
antifungal drugs21, suggesting the ability to incorporate any aptamer into this process. 
 
Methods  
Growth of Large-Area graphene by CVD. CVD graphene was grown in a 4 inch furnace on a 
copper foil substrate (99.8%, 25 µm, Alfa Aesar) using methane gas as a carbon source and H2 
(99.999% pure) as the carrier gas. The foil was placed in a low-pressure, 4” CVD furnace which 
heated to a temperature of 1020 °C with an H2 flow rate of 80 sccm. After reaching this 
temperature, the Cu foil was annealed for one hour, with the H2 flow rate constant at 80 sccm. 
Following the anneal step, methane gas was introduced at 10 sccm, and flowed for 20 minutes. 
After growth, the furnace was cooled to room temperature before the furnace was vented with N2 
gas and the foil was removed.   
Graphene Transfer: A sacrificial layer of poly methyl methacrylate (PMMA) was spin-coated onto 
the graphene/copper substrate for structural support, and the graphene was transferred via a 
hydrolysis bubble transfer method13 utilizing a 0.05M NaOH solution in deionized water. A 
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potential difference of 20V was applied across the foil as it entered the NaOH bath, with the 
cathode attached to the foil and the anode in the NaOH solution. As a result, the graphene-PMMA 
stack lifted off the foil due to the formation of H2 bubbles at the interface of the graphene and 
copper. After transferring the film to a series of water baths for cleaning, the film was finally 
transferred onto a 2 x 2.5 cm SiO2/Si chip with a pre-patterned array of Cr/Au (5nm/40nm) metal 
contact electrodes. The sample was left to dry for ~1 hour, and it was then baked at 150 °C for 2 
minutes to further improve adhesion. After this, the PMMA was removed with acetone.  
 
GFET Fabrication: A protective layer of polymethylglutarimide (PMGI, Microchem) was spin 
coated onto the surface of the graphene (4000 rpm, 45 seconds) and baked at 125 °C for 5 
minutes. Next, a layer of S1813 photoresist (Microchem) was spin coated onto the sample (5000 
rpm, 45 seconds) and baked at 100 °C for 2 minutes. GFET channels were defined using photo-
lithography. The excess graphene outside the channels was removed via O2 plasma etching (1.25 
Torr, 50 W, 30 sec), and the remaining photoresist was removed by soaking the chip in acetone 
(5 min), 1165 (Microposit, 5 min), and acetone (30 min) before finally being sprayed with isopropyl 
alcohol (IPA) and dried with compressed N2 gas. The devices were then cleaned of processing 
residues by annealing in a1” furnace at ambient pressure under a flow of 250 sscm H2 and 1000 
sccm Ar at 225 °C for one hour.  
 
GFET Functionalization and Testing: To functionalize the GFET channels, the chip was placed 
in a solution of 25 mL of dimethylformamide (DMF, Thermo Fisher) and 2 mg of 1-Pyrenebutyric 
acid N-hydroxysuccinimide ester (P-BASE, Sigma Aldrich), for 20 hours. After this time, the chip 
was removed, sprayed with DMF and soaked in DMF (2 min), sprayed with IPA and soaked in 
IPA for 2 min, and finally, sprayed with DI water and soaked in DI water (2 min) before being 
removed and dried with compressed N2 gas. AFM imaging of samples after this attachment step 
showed a height of ~2 nm for graphene plus P-BASE (data not shown). To prepare the aptamer 
 10 
solution, 10 µL of a 100 µM aptamer/DI water solution was diluted in 10 mL of phosphate buffer 
solution (MgCl2, 1mM, pH = 7.4), which was heated from 35 °C to 90 °C, held at 90 °C for 15 
minutes, and cooled to room temperature to obtain the necessary configuration of the aptamer. 
The devices were incubated in this solution for 3 hours. After aptamer attachment (which further 
increased the AFM height to ~3 nm for graphene, P-BASE and aptamer, as seen in Fig. 1e), the 
array was thoroughly cleaned with DI water.  
 
The I-Vg curves of the aptamer functionalized GFET array were measured using a bias voltage 
of 100 mV, while the gate voltage was swept over the range 0 – 90 V, with a step size of 2V and 
a scan rate of ~ 0.3 V/s. Next, a tenofovir/DI water solution of known concentration was pipetted 
onto the chip and left to incubate for one hour in a humid environment to prevent evaporation of 
the solution and allow for specific binding of tenofovir to the aptamer surface. After incubation, 
the sample was again thoroughly washed with DI water and blown dry. Finally, the I-Vg curves 
were measured again, and the data was analyzed to determine the Dirac voltage shift due to 
target binding. 
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